Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, University Hospital Groβhadern, Ludwig Maximilians-University, Munich. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich. In addition, he was visiting scientist at the University of Chicago 1992-1995.
His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation and secondary genetic alterations as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including novel antibodies and molecular targeted approaches like inhibitors of the B-cell receptor pathway.
Prof. Dreyling is Coordinator of the European MCL Network and Assistant Coordinator of the German Low Grade Lymphoma Study Group. He has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals.